1. Home
  2. COOK vs ENTX Comparison

COOK vs ENTX Comparison

Compare COOK & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Traeger Inc.

COOK

Traeger Inc.

HOLD

Current Price

$28.17

Market Cap

83.7M

ML Signal

HOLD

Logo Entera Bio Ltd.

ENTX

Entera Bio Ltd.

HOLD

Current Price

$1.12

Market Cap

74.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COOK
ENTX
Founded
1985
2010
Country
United States
Israel
Employees
N/A
N/A
Industry
Wholesale Distributors
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.7M
74.7M
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
COOK
ENTX
Price
$28.17
$1.12
Analyst Decision
Hold
Strong Buy
Analyst Count
5
1
Target Price
$58.00
$10.00
AVG Volume (30 Days)
535.0K
104.7K
Earning Date
03-05-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.18
Revenue
$559,520,000.00
$181,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$5.50
N/A
P/E Ratio
N/A
$6.56
Revenue Growth
N/A
N/A
52 Week Low
$0.48
$1.00
52 Week High
$35.56
$3.22

Technical Indicators

Market Signals
Indicator
COOK
ENTX
Relative Strength Index (RSI) 79.73 36.77
Support Level $0.98 $1.00
Resistance Level N/A $1.61
Average True Range (ATR) 1.45 0.16
MACD 3.40 -0.01
Stochastic Oscillator 77.71 6.12

Price Performance

Historical Comparison
COOK
ENTX

About COOK Traeger Inc.

Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

Share on Social Networks: